Clinical Trial Search

Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants

Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min

Primary: Number of Participants With Acute Cellular Rejection Between Study and Control Groups — 1; 1 Participants

Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants

Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL

Primary: Proportion of Participants Who Have Graft Loss or Death — 0.22 Proportion of Participants

Primary: Early Allograft Dysfunction — 6; 18 Participants

Primary: HCV RNA Result — 924,082; 3,731,749 IU/ml

Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…

Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants

Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants

Primary: Peak Aspartate Aminotransferase Within First 72h Post Transplant — 1262.9; 1451.2 U/L

Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m

Primary: Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection — 0; 0; 0; 2 participants

Primary: Participants Who Have Recovered Renal Function — 28; 20; 11 Participants

Primary: Amount of Treg Cells Observed in Peripheral Blood in Patients With and Without Rejection — 10; 5 percentage of CD4 positive cell

Primary: Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation — 8; 26 Participants

Primary: Graft Survival Rate — 100; 94.7; 90; 84 percentage of participants

Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants

Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants

Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants

Primary: Estimated Glomerular Filtration Rate (GFR) — 73.46; 71.95 mL/min — p=0.097

Primary: Proportion of Safety Events — 1 Participants

Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events

Primary: Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation — 8; 15…

Primary: Serum Creatinine Concentration — 112 umol/L

Primary: Side Effect of Cadaveric Donor Liver NK Cell Infusion — 0; 0 participants

Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants

Primary: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology at 12 Months — 8 Participants

Primary: Incidence Rate of Composite Efficacy Failure From Randomization to Month 12 — 6.7; 24.2; 9.7 Percentage of participants